Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers
Singlera Genomics raises $150 million in Series B financing to promote the development and commercialization of early cancer screening products
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
Foundation Medicine Acquires Lexent Bio, Inc., to Accelerate Liquid Biopsy Research and Development, and Advance Cancer Care
Base Genomics announces company launch and raises $11 million USD to commercialize epigenetic technology for early and sensitive detection of cancer from liquid biopsy
2019 in Review – Major Acquisitions, Population Studies, Gigantic Founding Rounds, Technological Advancements, and ….